


# BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

LIMITED)

(Formerly Known as SUN TECHNO OVERSEAS

Date: 23.07.2025

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 531752      Security ID: BIOGEN

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting of the board held on 23<sup>rd</sup> July 2025.**

**Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Wednesday 23<sup>rd</sup> July 2025** at the Registered Office of the Company and transacted the following major businesses:

1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2025.

The board meeting commented at 04:15 PM and concluded at 04:40 PM

Please take the above intimation in your records.

Thanking You,

**FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED**

KELASH  
BUNKAR

Digitally signed by Kelash Bunkar  
DN: cn=Kelash Bunkar, o=Biogen Pharmachem Industries Limited, email=kelash.bunkar@biogenpharmachem.com, c=IN

**KELASH BUNKAR  
WHOLETIME DIRECTOR**

**Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001**  
**E mail [biogenpharmachem@gmail.com](mailto:biogenpharmachem@gmail.com)**

# Biogen Pharmachem Industries Ltd

CIN:- L51100GJ1995PLC026702  
 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001  
 Email:- suntechnooverseas@gmail.com

(Rs. In lacs)

## Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2025

Sl no.	Particulars	Quarter Ended			Year Ended
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	<b>(Refer Notes Below)</b>	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	<b>INCOME</b>				
(a)	Gross Revenue from sale of products	-	-	-	-
(b)	Other Operating Revenue	154.28	135.23	(9.09)	83.84
<b>1</b>	<b>Revenue from Operations</b>	<b>154.28</b>	<b>135.23</b>	<b>(9.09)</b>	<b>83.84</b>
<b>2</b>	<b>Other Income</b>	-	-	-	-
<b>3</b>	<b>Total Income</b>	<b>154.28</b>	<b>135.23</b>	<b>(9.09)</b>	<b>83.84</b>
	<b>EXPENSES</b>				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of Stock-in-Trade	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	6.33	9.33	1.38	16.79
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and amortization expense	-	-	-	-
(g)	Other expenses	13.47	8.12	5.35	96.32
<b>4</b>	<b>Total Expenses</b>	<b>19.80</b>	<b>17.45</b>	<b>6.73</b>	<b>113.11</b>
<b>5</b>	<b>Profit / (Loss) from operations before exceptional items Tax (1-2)</b>	<b>134.48</b>	<b>117.78</b>	<b>(15.83)</b>	<b>(29.27)</b>
6	Exceptional Items	-	-	-	-
<b>7</b>	<b>Profit / (Loss) before Tax (5 ± 6)</b>	<b>134.48</b>	<b>117.78</b>	<b>(15.83)</b>	<b>(29.27)</b>
8	Tax Expense	-	-	-	-
<b>9</b>	<b>Net Profit / (Loss) after Tax (7 - 8)</b>	<b>134.48</b>	<b>117.78</b>	<b>(15.83)</b>	<b>(29.27)</b>
10	Other Comprehensive Income (net of tax )	-	-	-	-
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>11</b>	<b>Total Comprehensive Income for the period (9 ± 10)</b>	<b>134.48</b>	<b>117.78</b>	<b>(15.83)</b>	<b>(29.27)</b>
12	Paid-up equity share capital (Face Value of Rs.1/- each)	<b>9,026.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>
13	Other Equity	-	-	-	(903.26)
14	<b>Earnings Per Share (of Rs. 1/- each) (not annualised):</b>				
	(a) Basic	0.01	0.02	(0.00)	(0.00)
	(b) Diluted	0.01	0.02	(0.00)	(0.00)

**Notes:**

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 23, 2025. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board  
 For, Biogen Pharmachem Industries Ltd

KELASH  
 BUNKAR

Kelash Bunkar  
 Whoetime-Director  
 DIN: 10911360

Place : Rajkot  
 Date : 23rd July, 2025



# RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.  
Tel.: 9820501848, Email : rishisekhri@gmail.com

**Limited Review Report on unaudited standalone financial results of Biogen Pharmachem Industries Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Biogen Pharmachem Industries Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Biogen Pharmachem Industries Limited** for the quarter ended **30 June 2025** ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Rishi Sekhri and Associates  
Chartered Accountants

FRN: 128216W

CA Rishi Sekhri  
Partner

NO. 126656

PLACE: Mumbai

Date: 23/07/2025

UDIN: 25126656TKNCVN6857

